MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
MaxCyte, Inc.NASDAQ: MXCT
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital declines year over year
Q1 FY2026 change in working capital of $5.6M (cash outflow) fell 27.2% year over year, behind the -19.5% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +24.0% a year.
Context
- Change in working capital amounted to 18.5% of revenue in FY2025, up 16.6 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -27.2% toward the trailing-twelve-month pace of -19.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (6.12M) USD
- Year-over-year change
- -715.4%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.12M) | -715.4% |
| FY2024 | 2024-12-31 | (751K) | -119.7% |
| FY2023 | 2023-12-31 | 3.82M | +219.0% |
| FY2022 | 2022-12-31 | (3.21M) | -95.2% |
| FY2021 | 2021-12-31 | (1.64M) | — |
Change in Working Capital vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's LTM Mar 2026 change in working capital of $4.03M is the 5th largest of the 11 companies compared; the peer median is $341K.
- Its year-over-year change of -19.5% is the 6th highest of 10, against a peer median of +15.6%.
- Change in working capital amounts to 12.5% of revenue for MXCT, versus a peer median of 12.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.91M | +15.6% | -11.0% | 8.3% | |
| LTM Mar 2026 | $5.73M | -418.7% | -32.3% | 30.4% | |
| LTM Mar 2026 | $5.7M | -57.2% | -62.8% | 16.5% | |
| LTM Mar 2026 | $4.38M | +151.2% | — | 7.6% | |
| LTM Mar 2026 | $4.03M | -19.5% | +24.0% | 12.5% | |
| LTM Dec 2025 | $2.69M | +338.4% | — | 20.7% | |
| LTM Mar 2026 | $2.39M | — | — | 2.1% | |
| LTM Mar 2026 | $1.48M | -243.2% | +70.7% | 239.8% | |
| LTM Mar 2026 | $765K | +110.2% | -3.5% | 1.7% | |
| LTM Mar 2026 | $684K | +142.6% | — | 23.1% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $2K | -100.0% | — | 0.1% |
| Peer median (excluding MXCT) | $341K | +15.6% | -11.0% | 12.4% | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Depreciation & Amortization | 1.42M | 2.7M | 4.57M | 4.32M | 5.14M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.96M | 0 | 13.98M | 0 | 9.21M |
| Change in Working Capital | (1.64M) | (3.21M) | 3.82M | (751K) | (6.12M) |
| Accounts Receivables | (1.71M) | (6.69M) | 7.14M | 1.23M | 1.15M |
| Inventory | (1.41M) | (3.49M) | (4.53M) | 1.36M | 575K |
| Accounts Payables | 2.09M | (149.7K) | 3.25M | (1.88M) | (3.72M) |
| Other Working Capital | (624.7K) | 7.12M | (2.04M) | (1.46M) | (4.13M) |
| Other Non-Cash Items | 664.6K | 9.3M | (6.13M) | 9.88M | 1.99M |
| Operating Cash Flow | (10.68M) | (14.78M) | (21.69M) | (27.61M) | (34.41M) |
| Capital Expenditures | (3.83M) | (18.48M) | (3.7M) | (1.65M) | (1.77M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (1.77M) |
| Purchases of Investments | (268.68M) | (290.94M) | (255.1M) | (150.86M) | (126.29M) |
| Sales of Investments | 77.5M | 284.6M | 313.77M | 159.44M | 155.76M |
| Other Investing Activities | 4.6K | 0 | 9K | 0 | 0 |
| Investing Cash Flow | (195.01M) | (24.82M) | 54.98M | 6.93M | 25.94M |
| Debt Repayment | (4.99M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 236.08M | 2.89M | 269K | 2.06M | 656K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.63M | 0 | 1.87M | 0 | 0 |
| Financing Cash Flow | 234.72M | 2.89M | 2.14M | 2.06M | 656K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.03M | (36.72M) | 35.44M | (18.62M) | (7.82M) |
| Free Cash Flow | (14.51M) | (33.26M) | (25.39M) | (29.26M) | (36.18M) |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.